University of Cambridge develops world-first AI-designed vaccine that passed human trials
The University of Cambridge and biotech firm DIOSynVax Ltd announced on June 5 that a Phase I clinical trial of 39 healthy volunteers showed their AI-designed vaccine is safe, well-tolerated, and triggered immune respons…